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The onset of coronary artery disease (CAD) is influenced by cardiovascular risk factors that often occur in clusters
and may build on one another. The objective of this study is to examine the relationship between hypertension
and CAD age of onset in the Lebanese population.
This retrospective analysis was performed on data extracted from Lebanese patients (n = 3,753). Logistic regression
examined the association of hypertension with the age at CAD diagnosis after controlling for other traditional risk
factors. The effect of antihypertensive drugs and lifestyle changes on the onset of CAD was also investigated.
Results showed that hypertension is associated with late onset CAD (OR=0.656, 95% CI=0.504-0.853, p=0.001).
Use of antihypertensive drugs showed a similar association with delayed CAD onset. When comparing age of onset
in CAD patients with traditional risk factors such as hypertension, diabetes, hyperlipidemia, obesity, smoking and
family history of CAD, the age of onset was significantly higher for patients with hypertension compared to those
with any of the other risk factors studied (p < 0.001).
In conclusion, hypertension and its treatment are associated with late coronary atherosclerotic manifestations in Lebanese
population. This observation is currently under investigation to clarify its genetic and/or environmental mechanisms.
Keywords: Hypertension; Coronary artery disease (CAD); Risk factors; Antihypertensive drugs; Therapeutic lifestyle
changes; Lebanese populationIntroduction
Cardiovascular diseases have become a very prevalent
public health problem in both developed and developing
countries. In Lebanon, coronary artery disease (CAD) is
believed to be one of the leading causes of death (Sibai
et al. 2001). CAD risk factors were first described in stud-
ies in the mid-twentieth century (Dawber et al. 1959;
Arnaout et al. 2011). Hypertension, one of the most trad-
itional risk factors, has been consistently correlated with
increased probability of developing CAD in various popula-
tions (Dawber et al. 1959; Lewington et al. 2002; Lakka
et al. 1999; Collins et al. 1990; MacMahon et al. 1990). The
epidemiological studies are supported by experimental evi-
dence postulating that hypertension predisposes to athero-
sclerosis through a shared synergistic mechanism involving* Correspondence: pierre.zalloua@lau.edu.lb; aa14@aub.edu.lb
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in any medium, provided the original work is pinflammation and oxidative stress in the arterial wall
(Li JJChen 2005; O'Keefe et al. 2009).
The association of hypertension with CAD manifesta-
tions onset has not been thoroughly investigated in Middle
Eastern populations. A limited number of studies showed
that there is a significant association between hypertension
and acute myocardial infarction (MI) in older patients
(Sengul et al. 2011; Zuhdi et al. 2013). One study however
described hypertension as one of the most frequent risk
factors for premature CAD (Sadeghi et al. 2013).
It is conceivable that the effect of hypertension on CAD
disease onset may be modulated by various environmental
and genetic factors. However, it is widely accepted that
strategies adopted to lower blood pressure play a protect-
ive role by delaying atherosclerotic lesion formation
(Simon ALevenson 2002; Tropeano et al. 2011).
The present study was designed to investigate the as-
sociation between hypertension and CAD age of onset
in Lebanese patients who were recruited as part of an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Descriptive statistics of patients population
(n (% by column))
Early CAD Late CAD Total
n = 415 n = 3338 n = 3753
Age 47.0 ± 6.7 64.7 ± 9.5 62.4 ± 10.9
Age of onset 44.6 ± 6.0 62.9 ± 9.7 61.0 ± 11.0
Gender Male 218 (52.5) 2486(74.5) 2704 (72)
Female 197 (47.5) 852 (25.5) 1049 (28)
Diabetes No 288 (69.4) 2175 (65.2) 2463 (65.6)
Yes 127 (30.6) 1163 (34.8) 1290 (34.4)
Hypertension No 192 (46.3) 1163 (34.8) 1355 (36.1)
Yes 223 (53.7) 2175 (65.2) 2398 (63.9)
Hyperlipidemia No 182 (43.9) 1592 (47.7) 1774 (47.3)
Yes 233 (56.1) 1746 (52.3) 1979 (52.7)
Obesity No 230 (55.4) 2050 (61.4) 2280 (60.8)
Yes 185 (44.6) 1288 (38.6) 1473 (39.2)
Smoking No 111 (26.7) 1185 (35.5) 1296 (34.5)
Yes 304 (73.3) 2153 (64.5) 2457 (65.5)
FxCAD No 100 (24.1) 1339 (40.1) 1439 (38.3)
Yes 315 (75.9) 1999 (59.9) 2314 (61.7)
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project. Furthermore, the association of pharmacological
and non-pharmacological anti-hypertensive strategies
was examined.
Methods
Study subjects and collection of data
A total of 5,347 Lebanese patients undergoing cardiac
catheterization were sequentially enrolled for the FGENT-
CARD study (Youhanna et al. 2010) as part of a multi-
center cross-sectional study conducted at the Lebanese
American University, the Rafic Hariri University Hospital
and the “Centre Hospitalier du Nord” Lebanon, between
May 2007 and June 2010. The Institutional Review Board
at the Lebanese American University approved the study
protocol and all subjects gave informed consent before
their enrollment. Catheterization was performed by
Judkins’ technique.
Among the 5,347 enrolled subjects, 1,594 had no or
minor observable lesions in all coronary arteries and
3,753 patients presented coronary lesions that are classi-
fied as mild (≤50% stenosis in at least one vessel) or se-
vere (>50% stenosis in one or more of the coronary
arteries). The age of CAD onset was defined as the age
upon first diagnosis of CAD by catheterization. Since
gender is known to influence disease onset (Abchee
et al. 2006), male patients in our study population were
categorized as having early onset CAD if diagnosed at an
age younger than or equal to 45 (≤45), while female pa-
tients were categorized as having early onset CAD when
diagnosed at an age younger than or equal to 55 (≤55).
Accordingly, the 3,753 CAD patients were divided into
two groups: early onset CAD (n = 415) and late onset
CAD (n = 3,338) depending on their age at diagnosis.
A questionnaire specifically developed to measure the
impact of CAD risk factors and family history of CAD
(FxCAD) was duly filled and signed by each participant.
Diabetes, hypertension and hyperlipidemia were noted
when the condition was reported by an ascertained phys-
ician. Body Mass Index (BMI) was calculated according to
standard measurements. Smokers were defined as subjects
who smoked cigarettes before or at the time of enrollment
for the study. Physical activity level was determined ac-
cording to the daily number of exercising hours (inactive,
moderate activity, and regular exercise). Annotations were
coded from medical charts for additional data such as la-
boratory tests, nutritional diet (normal or low-salt), pre-
scribed medications, and presence of other diseases and
conditions (Youhanna et al. 2010).
Regression models and statistical analysis
A binomial logistic regression model was used to estimate
the odds of having an early onset (1) versus late onset
CAD (0) using the covariates: hypertension, lifestylechanges (being on a low-salt diet, and reporting moderate
or regular physical activity) and the use of one or more
anti-hypertensive drug. Odds ratios were adjusted after
controlling for cofounding variables (smoking, obesity,
diabetes, hyperlipidemia, and FxCAD) as well as for use
of other drugs (metabolic, anticoagulants and anti-
arrhythmics: data not shown).
In addition, we compared CAD age of onset between
different patients groups based on the presence or ab-
sence of hypertension combined with one or more CAD
traditional risk factors. The age of onset of CAD among
these different groups was compared using an Analysis
of Variance (ANOVA) test and the Tukey Honest Signifi-
cant Differences (TukeyHSD) test was performed for
paired multiple comparisons.
The R statistical software (version 2.14) was used for
the analysis and the glm (generalized linear models)
function from the “stats” package was used for building
the logistic regression model. A p value of 0.05 indicated
statistical significance. The average area under the curve
(AUC) was computed for the logistic regression model.
Results
The study population consisted of 72% males and 28% fe-
males. Mean CAD age of onset was 61.0 ± 11.0 years (early
CAD onset average age: 44.6 ± 6.0 years, late CAD onset
average age: 62.9 ± 9.7 years). 11.1% of patients had early
CAD onset. Table 1 describes the distribution of patients
according to CAD associated risk factors. The dominant
majority of CAD cases were associated with at least one
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blood pressure. CAD patients with no risk factor repre-
sented only 1.7% of the total population.
Association of risk factors with early vs. late CAD onset
A logistic regression model (Table 2) was built to assess
the impact of various risk factors on disease onset (early
versus late CAD). This model showed that smoking
(OR = 1.864, p < 0.001), obesity (OR = 1.237, p < 0.05)
and FxCAD (OR = 1.968, p < 0.001) were positively asso-
ciated with early onset of CAD, contrary to hyperlipid-
emia and diabetes which did not show significant
association with early disease onset (p > 0.05).
Hypertension and the use of anti-hypertensive drugs were
separately significantly associated with late onset of CAD
(OR = 0.656, p = 0.001; OR = 0.635, p = 0.001, respectively).
Lifestyle changes were not significantly associated with
early CAD onset (OR = 1.804, p > 0.05). The AUC of the lo-
gistic regression model was found to be 0.684.
Most CAD patients (69.8%, n = 2935) were treated with
antihypertensive drug(s); among them, 43% (n = 1263) re-
ceived a single drug which was for most cases (52.81%, n =
667) a β-blocker. The following were the antihypertensive
drugs reported by our study patients: Calcium Channel
Blockers (CCBs), β-blockers, Angiotensin Conversion
Enzyme Inhibitors (ACEIs), Angiotensin II Antagonists
(AIIAs) and diuretics.
Comparison of age of CAD onset between risk
factors groups
When comparing CAD age of onset among patients with
various risk factors, results showed that there is a signifi-
cant effect of risk factors on the age of onset of CAD
(ANOVA test, p < 0.001). In addition, paired comparisons
using the TukeyHSD test showed that the age of onset of
CAD in patients with hypertension was significantly
higher than the age of onset of CAD in patients with any
one or more of the other risk factors (Figure 1A). The dif-
ference in CAD age of onset persisted when patients wereTable 2 Adjusted odds ratios predicting early CAD as
outcome variable
Early onset CAD
odds ratio
95% confidence
interval (CI)
p value
Hypertension 0.656 0.504-0.853 0.0016
Anti-hypertensive
drugs
0.635 0.483-0.836 0.0011
Lifestyle changes 1.804 0.985-3.647 0.0746
Smoking 1.864 1.466-2.387 <0.001
Obesity 1.273 1.023-1.583 0.0300
Diabetes 0.803 0.625-1.025 0.0812
Hyperlipidemia 1.132 0.909-1.411 0.2695
FxCAD 1.968 1.551-2.516 <0.001subdivided according to gender (Figure 2). Furthermore,
CAD age of onset decreased significantly when two or
more risk factors were considered in addition to hyperten-
sion (Figure 1B).
Discussion
The major finding of this analysis is that hypertension
and its treatment were found to be independently asso-
ciated with CAD onset at a later age.
Relationship between hypertension and CAD
This study represents a primary analysis of the relation-
ship between hypertension and time of CAD diagnosis
in the Lebanese population. Although previous studies
conducted confirm the strong relationship between
hypertension and ischemic heart disease in general, it is
clear that differences exist between populations on how
hypertension affects CAD especially that few studies in-
vestigated the direct association between presence of
hypertension and onset of CAD (Benfante et al. 1989;
Chen et al. 1995; Menotti et al. 2004). Hypertension, as
well as diabetes, were dominant risk factors in the older
CAD group in a large study done on 15,381 CAD pa-
tients in Germany (Reibis et al. 2012). In a population of
men of Japanese ancestry, hypertension had a similar ef-
fect on both early and delayed CAD (Benfante et al. 1989).
In a selective population of Canadian patients, the relative
risk of high blood pressure for ischemic heart disease, de-
clined with advancing age (Tate et al. 1998). In a study aim-
ing to explore the association of major coronary risk
factors with CAD in a sub-population of men in the United
States, it was found that risk of coronary death increased
with time as a function of blood pressure (Menotti et al.
2004). In the Middle East countries, limited studies investi-
gated the association between high blood pressure and
CAD. While most of them found an association between
hypertension and late CAD manifestations (Sengul et al.
2011; Zuhdi et al. 2013), one study reported hypertension
as one of the most frequent risk factors in premature CAD
(Sadeghi et al. 2013). These differences highlight the fact
that socioeconomic, environmental and genetic factors play
a determining role in the development of cardiovascular
diseases (Watson KETopol 2004).
In the Lebanese population, the prevalence of hyperten-
sion has been estimated at 23.1% in a representative
sample of the general population and it was higher in the
less educated and unemployed (Tohme et al. 2005). The
pathogenesis of hypertension includes the interaction of
genetic and environmental factors including abnormalities
of fluid volume regulation, increased vasoconstriction, and
remodeling of the vascular wall (decreasing diameter and
increasing resistance). The mechanisms by which hyper-
tension would trigger atherosclerosis have not been well
elucidated. Dysfunctional vascular endothelium leads to
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Figure 1 Comparison between the mean ages of onset (±95% CI) of CAD among several groups of CAD patients sorted according to
the associated risk factors (RF). CAD patients within the group “hypertension” had only hypertension as RF. The group “no RF” had no
observed or documented RF. A. CAD age of onset in non-hypertensive patients with cumulative RF was compared between the various CAD
groups (ANOVA) and then each group to the “hypertension” group (Tukey HSD). CAD patients within group “no hypertension + 1 RF” had any of the
following RF: smoking, obesity, diabetes, hyperlipidemia and FxCAD, but did not have hypertension. In subsequent groups, CAD patients had any two,
three, four or all five RF, but no hypertension. (*p < 0.05, **p < 0.01, ***p < 0.001 vs. hypertension group). B. CAD age of onset in hypertensive patients with
cumulative RF was compared between the various CAD groups and then each group to the “hypertension” group. CAD patients in group “hypertension +
1 RF” had hypertension in addition to anyone of the other previously mentioned RF. In subsequent groups, CAD patients with hypertension had any two,
three, four or all five additional RF. HSD (*p < 0.05, **p < 0.01, ***p < 0.001 vs. hypertension group).
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Angiotensin II, through activation of the AT-1 receptor,
induces generation of inflammatory mediators and react-
ive oxygen species in the blood vessel wall and as such
plays an active role in the inflammation process (MacKenzie
2011; Alexander 1995). These mechanisms are all slow
grade processes that take years to develop. This can partially
explain our finding that hypertension was associated with
late rather than early CAD.
Anti-hypertensive strategies and CAD
Moreover, the use of anti-hypertensive drugs showed an
association with late CAD as outcome variable. This resultis expected since most anti-hypertensive drugs, in addition
to reducing blood pressure, are known to be beneficial in
lowering cardiovascular disease risks in general. The pres-
ervation or recovery of endothelial function in hypertensive
patients is crucial to inhibit the development of athero-
sclerosis and the onset of cardiovascular events. β-blockers
improve endothelium-dependent vasodilation, decrease
peripheral vascular resistance, and were also shown to have
some antioxidant effects (Alexander 1995; Balligand 2009).
According to a recent analysis of randomized trials that
used ultrasound imaging to measure changes in vascular-
disease severity over time, long-term β-blocker therapy was
associated with a reduction in atheroma volume (Sipahi
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Figure 2 Mean age (±95% CI) distribution of CAD age of onset according to gender (black for men and grey for women). CAD patients
within the group “hypertension” had only hypertension as RF. The group “no RF” had no observed or documented RF. CAD age of onset in
non-hypertensive patients with cumulative RF was compared between the groups (ANOVA) and then each group to the “hypertension” group
(Tukey HSD). CAD patients within group “no hypertension + 1 RF” had any of the following RF: smoking, obesity, diabetes, hyperlipidemia and
FxCAD, but did not have hypertension. In subsequent groups, CAD patients had any two, three, four or all five RF, but no hypertension.
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ized prospective trial, INVEST, focusing on CAD patients
with hypertension, it was found that treatment strategies
utilizing a calcium-channel blocker (CCB) or a β-blocker
prevent all-cause mortality and non-fatal myocardial infarc-
tion (Pepine et al. 2003). Moreover, ACEIs protect the
endothelium from oxidative stress by inhibiting the
formation of Angiotensin II, a potent inducer of reactive
oxygen species production in vascular cells (White 2007).
AIIAs activate bradykinin B2 receptor-mediated nitric
oxide production. Both ACEIs and AIIAs, have been shown
to reduce atherosclerotic lesion formation (Yusuf et al.
2000; Dahlof et al. 2002; Besler et al. 2008) and intima-
media thickness (Cuspidi et al. 2009). Finally, diuretics re-
duce significantly the occurrence of cardiovascular disease
(Psaty et al. 2003) and stroke (Papp et al. 2012).
The logistic regression model corrected the odds ratio of
hypertension for the effect of both the pharmacological
treatment and lifestyle changes. This seems to favor the
hypothesis that other population-specific genetic and/or
nutritional factors would explain the observed significant
association of hypertension with the late CAD onset in our
population.
Many studies have documented genetic susceptibilities to
CAD and hypertension, however to-date, these resultscould not confirm the presence of common susceptibility
variants for these two diseases (Slavin et al. 2011; Zhu et al.
2010; Ioannidis 2009). The most current Genotypes and
Phenotypes database (dbGaP) lists 29 genetic variants
associated with hypertension and 69 associated with CAD.
None of these genetic variants overlaps, suggesting the
need for additional genome-wide association studies that
can unravel common genetic pathways between these two
clinically related diseases and identify variants that modulate
CAD age of onset in hypertensive patients.
Study limitations
One of the main limitations of the current study is the
lack of information on the duration of hypertension and
the elapsed time before treatment initiation which are
modulating factors for CAD development.
Conclusions
Our study presents a primary general observation of the
association of hypertension and its treatment with CAD
development. Although suggestive, these findings need to
be substantiated by a prospective study that we are
currently conducting that would confirm our results after
controlling for duration since hypertension diagnosis as
well as initiation of treatment and therapy goals. Such a
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genetic and nutritional variants involved in this association.
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